Neurogene Inc.
NGNE · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $0 | $5 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $0 | $0 | $0 | $5 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | -$0 | -$0 | -$0 | -$0 |
| % Margin | -251% | – | – | – |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -7,771.4% | – | – | – |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -8,123.7% | – | – | – |
| EPS Diluted | -4.28 | -2.83 | -4.3 | -0.92 |
| % Growth | -51.2% | 34.2% | -367.4% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |